
# **Solitary Pulmonary Nodule**



Τζίλας Βασίλειος. Πνευμονολόγος Πανεπιστημιακός Υπότροφος, Μονάδα Διαμέσων Νοσημάτων Α' Πανεπιστημιακή Πνευμονολογική Κλινική, ΝΝΘΑ «Η Σωτηρία», ΕΚΠΑ


#### **Definition**

- Round or oval pulmonary parenchymal lesion, relatively well defined <u>≤3cm</u>
- Surrounded by pulmonary parenchyma and/or visceral pleura and is not associated with lymphadenopathy, atelectasis, or pneumonia

Lesions > 3 cm are considered masses and are treated as malignancies until proven otherwise.


### Measurement


- Contiguous <u>thin</u> sections (≤1.5 mm)
- Use image revealing the greatest dimension
- Use <u>average</u> diameter (it more accurately reflects three-dimensional tumor volume)
- Round to the <u>nearest</u> <u>millimeter</u>





# **Solitary Pulmonary Nodule**


- Differential diagnosis is extremely broad
- Important not to miss malignancy
- Avoid misdiagnosis













#### Size matters!!!

Size (mm)	(%) Malignancy	Total number
<4	0	2038
4-7	1	1034
8-20	15	268
>20	<b>7</b> 5	16


Patients with high risk for lung cancer

Stephen J. Swensen et al. CT Screening for Lung Cancer: Five-year Prospective Experience. Radiology 2005;235:259-265






#### Classification of SPN according to attenuation



# **Attenuation-Signs of benignity**

- Calcification in benign patterns
- Fat (-40 to -120 HU)


# **Calcification pattern in SPN**






Fat density recognized within nodules Smooth margins

**Compatible with hamartoma** 





## Margins


#### In favor of malignancy

- Lobulated
- Scalloped, spiculated
- Corona radiata

Adenocarcinoma

#### In favor of benignity

- Smooth, BUT
- 20% malignant
- 30% metastatic




Metastatic, nasopharyngeal cancer

# **Lobulated margins**




Squamous cell carcinoma


# Spiculated, irregular margins




Adenocarcinoma

# Pit-fall sign







# Air Bronchogram



Adenocarcinoma




Adenocarcinoma


The presence of air bronchograms and/or bubble-like lucencies should not mislead away from the possibility of malignancy

# Halo sign



Adenocarcinoma





#### **Contrast enhancement**

- Contrast enhancement <15 HU:</li>
- Very high predictive value for benignity (99%)
- Diagnosis of Pulmonary Arteriovenous Malformations

# **PAVM**





# **Prior imaging studies**



# PET/CT scan-False negatives


- Size <0,8-1cm
- Type of tumor


Iwano S et al. What causes false-negative PET findings for solid-type lung cancer? Lung Cancer. 2013;79(2):132-6.


# Examples of potentially negative FDG-PET malignancies

- Adenocarcinoma
- Carcinoid tumors
- Low grade lymphomas
- Renal cell carcinomas
- Hepatomas
- Mucinous tumors of the GIT

#### 61 year old male, right nephrectomy in 2006 due to kidney neoplasia









# Especially difficult to evaluate nodules <1cm

- PET is unreliable
- It is difficult to assess accurately morphology





# Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the

Fleischner Society 2017<sup>1</sup>

#### These guidelines **DO NOT** apply to patients:

- Younger than 35 years,
- Immunocompromised
- With known cancer
- Subjected to lung cancer screening

# When to follow up?

Minimum threshold size for recommending follow-up: <u>estimated cancer risk ≥ 1%</u>

# **Solid nodules**

Size (mm)	<6	6-8	>8
Low Risk	No routine follow up	CT at 6–12 months Consider CT at 18–24 months	Consider CT at 3 months, PET/CT, or tissue sampling
High Risk	Optional in 12 months	CT at 6–12 months Obtain CT at 18–24 months	


#### Solid nodules <6mm

- Risk of cancer in nodules <6 mm less than 1%, even in patients at high risk
- Suspicious morphology and/or upper lobe location can increase cancer risk into the 1%– 5% range
- Earlier follow-up is not recommended as such small nodules, if malignant, rarely advance in stage over 12 months

# **Subsolid nodule**

Size (mm)	≤6	>6
Ground Glass	No routine follow-up	CT at 6–12 months (confirm persistence), then CT every 2 years until 5 years
Part Solid	N/A	CT at 3–6 months (confirm persistence) If unchanged and solid component remains ≤6 mm, annual CT for 5 years.

# **Risk Factors for Malignancy**



#### **Brock model**

- Larger nodule size
- Spiculation
- Part-solid nodule type

Fibrosis!!!

- Older age
- Female sex
- Family history of lung cancer
- Emphysema
- Upper lobe nodule location
- Lower nodule count

McWilliams A, et al. Probability of cancer in pulmonary nodules detected on first screening CT. The New England journal of medicine. 2013;369 (10): 910-9

#### 67 year old man with progressive shortness of breath

#### At presentation



Upper lobe predominant centrilobular emphysema Irregular reticular pattern Traction bronchiectasis Honeycomb changes

**CPFE** 

At presentation After 1 year

**Enlarging lobulated nodule in the left upper lobe** 

# Take home messages

- SPN evaluation is multidimensional
- Begin by estimating pretest probability for malignancy
- Important radiological parameters
- √ Size
- ✓ Morphology
- ✓ Enhancement
- ✓ Location
- Science and Art: follow up vs invasive diagnosis

